eMedicine Specialties > Emergency Medicine > Gastrointestinal

Cholecystitis and Biliary Colic: Treatment & Medication

Author: Rahul Sharma, MD, MBA, FACEP, Assistant Professor, Weill Medical College of Cornell University; Attending Physician, Department of Emergency Medicine, New York Presbyterian Hospital-Weill Cornell Medical Center
Coauthor(s): Peter A D Steel, MA, MBBS, Staff Physician, Department of Emergency Medicine, Joan and Sanford I Weill Medical College of Cornell and Columbia University College of Physicians and Surgeons, New York Presbyterian Hospitals
Contributor Information and Disclosures

Updated: Jul 28, 2009

Treatment

Prehospital Care

  • Patients with gallbladder colic or cholecystitis usually present in the prehospital setting with severe abdominal pain. Transport patients with minor symptoms to the hospital with an IV in place and monitor. However, the diagnosis of cholecystitis is not a prehospital diagnosis.
  • In patients with severe pain (eg, differential includes abdominal aortic aneurysm, myocardial infarction) and in patients with hypotension and/or fever who may have cholecystitis or cholangitis, prehospital care should include the following:
    • As with all emergencies, airway, breathing, and circulation take priority and should be assessed immediately.
    • Monitoring (pulse oximetry, cardiac monitor, frequent blood pressure measurements, blood glucose measurement)
    • Stabilization (oxygen, placement of 2 large-bore IVs, administration of IV fluids to unstable patients)
    • Rapid transport

Emergency Department Care

  • Primary goal of ED care is stabilization of the patient and an expedient diagnosis.
  • Suspect gallbladder colic in patients with less than 4-6 hours of right upper quadrant pain that radiates to the back. Consider acute uncomplicated cholecystitis in patients with pain of longer duration and with or without low-grade fever. Severe cholecystitis can develop into sepsis or cholangitis, especially in patients with diabetes or elderly patients, in whom the diagnosis may be delayed.
  • After assessment of the ABCs, perform the standard opening gambit of IV, pulse oximetry, oxygen, ECG, and monitoring. Send labs when the IV is placed; include blood cultures if the patient is febrile.
  • Replace volume loss with normal saline, then maintenance fluids. Make patients nothing by mouth (NPO). Nasogastric suction may be needed in patients with persistent vomiting or abdominal distention.
  • In patients who are unstable or have severe pain, consider a bedside ultrasound to exclude an abdominal aortic aneurysm and assist in the diagnosis of cholecystitis.
  • In 2007, the unvalidated "Tokyo guidelines" were published, a set of clinical and radiological diagnostic criteria for acute cholecystitis. Patients exhibiting one of the local signs of inflammation, such as Murphy's sign, or a mass/pain/tenderness in the right upper quadrant, as well as one of the systemic signs of inflammation, such as fever, elevated white blood cell count, and elevated C-reactive protein level, are diagnosed as having acute cholecystitis. Imaging findings characteristic of acute cholecystitis confirm the diagnosis.6
  • Once diagnosis of acute cholecystitis is made, it usually is treated by hospitalization. This may include medical and/or surgical therapy. Some patients may be treated as outpatients.
  • The guidelines of the Infectious Diseases Society of America recommend that antimicrobial therapy be instituted if infection is suspected on the basis of laboratory and clinical findings (>12,500 WCC; temp >38.5°C) and radiographic findings (eg, air in the gallbladder or gallbladder wall).7
  • Antibiotics are also recommended for routine use in patients who are elderly or have diabetes or immunodeficiency and for prophylaxis in patients undergoing cholecystectomy to reduce septic complications even when infection is not suspected.8
  • Pain control considerations are as follows:
    • Several studies now have shown that early pain control in ED patients with abdominal pain does not hinder the diagnosis. Therefore, administer pain control early, without waiting for the diagnosis or surgical consult. A courtesy call to the surgical consultant prior to administration of narcotics offers the expedient opportunity to examine the patients without narcotics, which occasionally diminishes surgical resistance to prediagnosis narcotic use.
    • Pain control should be with opiate analgesics such as meperidine (Demerol). Morphine is generally not recommended since it can increase the tone of the sphincter of Oddi.
    • Anticholinergic antispasmodics, such as dicyclomine (Bentyl), are also recommended in the initial management of acute biliary colic and cholecystitis.
    • Anti-inflammatory medications such as ketorolac or indomethacin have been reported to be effective in relieving pain from gallbladder distention. Because the release of prostaglandins results in gallbladder distension, inhibition of these prostaglandins may help alleviate some of the symptoms. However, they may not be as effective when biliary colic is complicated by infection.
    • Antiemetics such as metoclopramide or prochlorperazine can be used.

Consultations

  • Historically, cholecystitis was operated on emergently, resulting in increased mortality. Currently, practice is to cool off the gallbladder and perform a cholecystectomy after several days or readmit the patient at a later date.
  • Emergent cholecystectomy is usually performed in 20% of cases of acute cholecystitis that has become complicated (ie, gangrene, perforation).
  • In high surgical risk patients, placement of a percutaneous cholecystostomy is an acceptable alternative and can be performed at the bedside with ultrasound guidance.
  • Prescribe an urgent gastroenterology consultation for ERCP for patients with evidence of choledocholithiasis (ie, common bile duct stones seen on sonography, dilated common bile ducts, elevated LFTs, pancreatitis).
  • Surgical consult is appropriate, and depending on the institution, either medicine or surgery may admit the patient for conservative care.

Medication

Although surgical therapy is treatment of choice for acute cholecystitis, many patients require hospitalization for stabilization and "cooling off" of the gallbladder prior to surgery. Indications for urgent surgical intervention include patients with complications such as empyema, emphysematous cholecystitis, or perforation. Medical therapy of gallbladder colic includes antiemetics and pain control. In mild cholecystitis, in which inflammation is the primary process, antibiotics are prophylactic but usually are used. In acute cholecystitis, broad-spectrum antibiotic coverage is used.

The following dosages are general recommendations. Please check current sources prior to administration.

Anticholinergics

Antispasmodics and anticholinergics are thought to decrease gallbladder and biliary tree tone, which decreases pain associated with gallstones.


Dicyclomine hydrochloride (Bentyl)

Has antimuscarinic and anticholinergic effects on smooth muscle. Moderately effective in reducing pain of gallbladder colic and cholecystitis. Used in many institutions as first-line pain control for this disease, with narcotics as second-line pain controllers. May not be given IV.

Adult

20 mg IM q4-6h; dosing range is 10-40 mg PO tid/qid

Pediatric

Not established

Effects are weakened when administered with anti-Parkinson drugs, haloperidol, and phenothiazines; toxicity of dicyclomine increases when administered concurrently with amantadine, antihistamines, type-I antiarrhythmics, phenothiazines, TCAs, or narcotic analgesics

Documented hypersensitivity; GI obstruction; ulcerative colitis; obstructive uropathy; reflux esophagitis; unstable cardiovascular status; glaucoma; myasthenia gravis

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Caution when administering to patients with hepatic or renal insufficiency, cardiovascular disease, urinary tract obstruction, ulcerative colitis, GI obstruction, hyperthyroidism, or hypertension


Glycopyrrolate (Robinul)

Use similarly to dicyclomine for anticholinergic effects. Acts in smooth muscle, CNS, and secretory glands, where blocks action of acetylcholine at parasympathetic sites.

Adult

1 tab PO tid

Pediatric

Not established

Levodopa decreases effects of glycopyrrolate; both amantadine and cyclopropane increase glycopyrrolate toxicity

Documented hypersensitivity; narrow-angle glaucoma; tachycardia; ulcerative colitis; paralytic ileus; acute hemorrhage; Down syndrome

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Glycopyrrolate may increase chances of developing megacolon, hyperthyroidism, CHF, CAD, hiatal hernia, and BPH; not recommended for children <12 y and patients with Down syndrome

Analgesics

When dicyclomine (Bentyl) is not effective, a narcotic is appropriate. The narcotic of choice is meperidine due to potential problems of increased tone of sphincter of Oddi with morphine.


Meperidine (Demerol)

Narcotic analgesic with multiple actions similar to those of morphine. However, may produce less constipation, smooth muscle spasm, and depression of cough reflex than similar analgesic doses of morphine.

Adult

25-75 mg IV/IM; repeat prn

Pediatric

0.5-0.8 mg/kg IV/IM

Monitor for increased respiratory and CNS depression with coadministration of cimetidine; hydantoins may decrease effects of meperidine; avoid with protease inhibitors

Documented hypersensitivity; MAOIs; upper airway obstruction or significant respiratory depression; during labor when delivery of premature infant is anticipated

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Caution in patients with head injuries, since meperidine may increase respiratory depression and CSF pressure (use only if absolutely necessary); caution when using postoperatively and with history of pulmonary disease (suppresses cough reflex)
Substantially increased dose levels, due to tolerance, may aggravate or cause seizures even if no history of convulsive disorders; monitor closely for morphine-induced seizure activity if seizure history

Antiemetics

Cholecystitis and particularly obstruction of common bile duct can cause nausea and vomiting; therefore, antiemetics can be helpful.


Promethazine HCl (Phenergan, Anergan, Prorex)

Antidopaminergic agent effective in treatment of emesis. Blocks postsynaptic mesolimbic dopaminergic receptors in brain and reduces stimuli to brainstem reticular system.

Adult

12.5-25 mg PO/IV/IM/PR

Pediatric

<2 years: Contraindicated
>2 years: 0.5 mg/kg PO/IV/IM/PR

May have additive effects when used concurrently with other CNS depressants or anticonvulsants; coadministration with epinephrine may cause hypotension

Documented hypersensitivity; children younger than 2 y (incidences of death due to respiratory depression)

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Intraarterial injection can cause spasm and gangrene; burning on administration may occur
Caution in cardiovascular disease, impaired liver function, seizures, sleep apnea, and asthma


Prochlorperazine (Compazine)

Antidopaminergic drug that blocks postsynaptic mesolimbic dopamine receptors, has anticholinergic effect, and can depress reticular activating system, possibly responsible for relieving nausea and vomiting.

Adult

5-10 mg PO/IV/IM/PR

Pediatric

0.03 mg/kg PO/IV/IM/PR

Coadministration with other CNS depressants or anticonvulsants may cause additive effects; with epinephrine may cause hypotension

Documented hypersensitivity; bone marrow suppression; narrow-angle glaucoma; severe liver or cardiac disease

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Drug-induced Parkinson syndrome or pseudoparkinsonism occurs quite frequently; akathisia is most common extrapyramidal reaction in elderly patients; lowers seizure threshold; caution with history of seizures

Antibiotics

Treatment of acute cholecystitis usually requires single-agent therapy, but for more serious infections, combination drug treatment has increased broad-spectrum coverage. Debate exists as to whether the most effective antibiotics must have high biliary concentrations. Antibiotics should be guided to target the most common organisms found in biliary tract pathology. These include E coli, Klebsiella species, and Streptococcus species.

Single-agent regimens include the following: piperacillin and tazobactam, ampicillin and sulbactam, mezlocillin, imipenem, meropenem, ticarcillin, and clavulanate.

Good combinations include the following: penicillin (including piperacillin, ampicillin, or penicillin) and metronidazole; the above plus an aminoglycoside (gentamicin or tobramycin); and aminoglycoside and third-generation cephalosporin.


Piperacillin/tazobactam (Zosyn)

Drug combination usually used in combination therapy. Antibiotic regimen needs to cover enteric microbes, including most common organisms: E coli (39%), Klebsiella species (54%), Enterobacter (34%), enterococci (34%), and group D streptococci.

Adult

3.375 g IV q6h

Pediatric

75 mg/kg IV q6h

Tetracyclines may decrease effects of ticarcillin; high concentrations of ticarcillin may physically inactivate aminoglycosides if administered in same IV line; effects when administered concurrently with aminoglycosides are synergistic; probenecid may increase penicillin levels

Documented hypersensitivity; do not treat severe pneumonia, bacteremia, pericarditis, emphysema, meningitis, and purulent or septic arthritis with an oral penicillin during acute stage

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Perform CBCs prior to initiation of therapy and at least weekly during therapy; monitor for liver function abnormalities by measuring AST and ALT during therapy; exercise caution in patients diagnosed with hepatic insufficiencies; perform urinalysis and BUN and creatinine determinations during therapy and adjust dose if values become elevated; monitor blood levels to avoid possible neurotoxic reactions


Mezlocillin (Mezlin)

During growth phase, interferes with bacterial cell wall synthesis, causing death in susceptible microorganisms. Has antipseudomonal activity.

Adult

3 g IV/IM q4h

Pediatric

Neonates: 75 mg/kg IV/IM bid
Infants and children <12 years: 50 mg/kg IV/IM q4h

Has synergistic effects when administered concomitantly with aminoglycosides; probenecid increases mezlocillin blood levels; duration of neuromuscular blockade increases when administered concurrently with vecuronium; enhances anticoagulant effects of heparin; may decrease effectiveness of oral contraceptives; bacteriostatic effects of tetracyclines may decrease effectiveness of penicillins

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Caution in preexisting sinus node dysfunction and renal impairment, bradycardias, antiarrhythmic agents, thrombocytopenia, electrolyte disturbances, or CHF


Imipenem and cilastatin (Primaxin)

For treatment of multiple organism infections in which other agents do not have wide-spectrum coverage or are contraindicated due to potential for toxicity. Reserve for very ill patients. May be used alone or in combination.

Adult

0.5 g IV q6h

Pediatric

<12 years: Not established; following dosing regimen has been suggested:
>3 months: 15-25 mg/kg/dose IV q6h
Fully susceptible organisms: Not to exceed 2 g/d IV
Infections with moderately susceptible organisms: Not to exceed 4 g/d

Coadministration with cyclosporine may increase CNS adverse effects of both agents; coadministration with ganciclovir may result in generalized seizures

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Adjust dose in renal insufficiency; avoid use in children <12 y


Cefoxitin (Mefoxin)

Second-generation cephalosporin indicated for management of infections caused by susceptible gram-positive cocci and gram-negative rods. Many infections caused by gram-negative bacteria, resistant to some cephalosporins and penicillins, respond to cefoxitin.

Adult

1 g IV q8-12h

Pediatric

<3 months: Not established
>3 months: 30-40 mg/kg IV q8-12h

Probenecid may increase effects of cefoxitin; coadministration with aminoglycosides or furosemide may increase nephrotoxicity (closely monitor renal function)

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged use or repeated treatment; caution in patients with previously diagnosed colitis


Gentamicin (Gentacidin, Garamycin)

Aminoglycoside antibiotic used for gram-negative bacterial coverage. Commonly used in combination with both an agent against gram-positive organisms and one that covers anaerobes.
Single daily dosing has not been well studied in cholangitis. Do not use if evidence of renal insufficiency exists.

Adult

3-5 mg/kg/d IV divided q8h

Pediatric

5-7 mg/kg/d IV divided q8h

Coadministration with other aminoglycosides, cephalosporins, penicillins, and amphotericin B may increase nephrotoxicity; aminoglycosides enhance effects of neuromuscular blocking agents, thus prolonged respiratory depression may occur
Coadministration with loop diuretics may increase auditory toxicity of aminoglycosides; possible irreversible hearing loss of varying degrees may occur (monitor regularly)

Documented hypersensitivity; nondialysis-dependent renal insufficiency

Pregnancy

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Narrow therapeutic index (not intended for long-term therapy); caution in patients with renal failure who are not on dialysis, myasthenia gravis, hypocalcemia, and conditions that depress neuromuscular transmission; adjust dose in renal impairment

More on Cholecystitis and Biliary Colic

Overview: Cholecystitis and Biliary Colic
Differential Diagnoses & Workup: Cholecystitis and Biliary Colic
Treatment & Medication: Cholecystitis and Biliary Colic
Follow-up: Cholecystitis and Biliary Colic
Multimedia: Cholecystitis and Biliary Colic
References

References

  1. Carter HR, Cox RL, Polk HC Jr. Operative therapy for cholecystitis and cholelithiasis: trends over three decades. Am Surg. Oct 1987;53(10):565-8. [Medline].

  2. Urbach DR, Stukel TA. Rate of elective cholecystectomy and the incidence of severe gallstone disease. CMAJ. Apr 12 2005;172(8):1015-9. [Medline].

  3. Singer AJ, McCracken G, Henry MC, et al. Correlation among clinical, laboratory, and hepatobiliary scanning findings in patients with suspected acute cholecystitis. Ann Emerg Med. Sep 1996;28(3):267-72. [Medline].

  4. Ralls PW, Colletti PM, Lapin SA, Chandrasoma P, Boswell WD Jr, Ngo C. Real-time sonography in suspected acute cholecystitis. Prospective evaluation of primary and secondary signs. Radiology. Jun 1985;155(3):767-71. [Medline].

  5. Kim CK, Tse KK, Juweid M, Mozley PD, Woda A, Alavi A. Cholescintigraphy in the diagnosis of acute cholecystitis: morphine augmentation is superior to delayed imaging. J Nucl Med. Nov 1993;34(11):1866-70. [Medline].

  6. [Guideline] Hirota M, Takada T, Kawarada Y, Nimura Y, Miura F, Hirata K. Diagnostic criteria and severity assessment of acute cholecystitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg. 2007;14(1):78-82. [Medline].

  7. [Guideline] Solomkin JS, Mazuski JE, Baron EJ, Sawyer RG, Nathens AB, DiPiro JT. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis. Oct 15 2003;37(8):997-1005. [Medline].

  8. Strasberg SM. Clinical practice. Acute calculous cholecystitis. N Engl J Med. Jun 26 2008;358(26):2804-11. [Medline].

  9. Adedeji OA, McAdam WA. Murphy's sign, acute cholecystitis and elderly people. J R Coll Surg Edinb. Apr 1996;41(2):88-9. [Medline].

  10. Morrow DJ, Thompson J, Wilson SE. Acute cholecystitis in the elderly: a surgical emergency. Arch Surg. Oct 1978;113(10):1149-52. [Medline].

  11. American College of Emergency Physicians. Emergency ultrasound imaging criteria compendium. Ann Emerg Med. Oct 2006;48(4):487-510. [Medline].

  12. Bennett GL, Balthazar EJ. Ultrasound and CT evaluation of emergent gallbladder pathology. Radiol Clin North Am. Nov 2003;41(6):1203-16. [Medline].

  13. Burrell MI, Zeman RK, Simeone JF, et al. The biliary tract: imaging for the 1990s. AJR Am J Roentgenol. Aug 1991;157(2):223-33. [Medline].

  14. Flasar MH, Cross R, Goldberg E. Acute abdominal pain. Prim Care. Sep 2006;33(3):659-84, vi. [Medline].

  15. Giurgiu DI, Roslyn JJ. Treatment of gallstones in the 1990s. Prim Care. Sep 1996;23(3):497-513. [Medline].

  16. Gruber PJ, Silverman RA, Gottesfeld S, Flaster E. Presence of fever and leukocytosis in acute cholecystitis. Ann Emerg Med. Sep 1996;28(3):273-7. [Medline].

  17. Houdart R, Perniceni T, Darne B, et al. Predicting common bile duct lithiasis: determination and prospective validation of a model predicting low risk. Am J Surg. Jul 1995;170(1):38-43. [Medline].

  18. Janowitz P, Kratzer W, Zemmler T, et al. Gallbladder sludge: spontaneous course and incidence of complications in patients without stones. Hepatology. Aug 1994;20(2):291-4. [Medline].

  19. Kim MK, Strait RT, Sato TT, Hennes HM. A randomized clinical trial of analgesia in children with acute abdominal pain. Acad Emerg Med. Apr 2002;9(4):281-7. [Medline].

  20. McHale PM, LoVecchio F. Narcotic analgesia in the acute abdomen--a review of prospective trials. Eur J Emerg Med. Jun 2001;8(2):131-6. [Medline].

  21. McSherry CK, Ferstenberg H, Calhoun WF, et al. The natural history of diagnosed gallstone disease in symptomatic and asymptomatic patients. Ann Surg. Jul 1985;202(1):59-63. [Medline].

  22. Moscati RM. Cholelithiasis, cholecystitis, and pancreatitis. Emerg Med Clin North Am. Nov 1996;14(4):719-37. [Medline].

  23. Saini S. Imaging of the hepatobiliary tract. N Engl J Med. Jun 26 1997;336(26):1889-94. [Medline].

  24. Shea JA, Berlin JA, Escarce JJ. Revised estimates of diagnostic test sensitivity and specificity in suspected biliary tract disease. Arch Intern Med. Nov 28 1994;154(22):2573-81. [Medline].

  25. Stevens KA, Chi A, Lucas LC, Porter JM, Williams MD. Immediate laparoscopic cholecystectomy for acute cholecystitis: no need to wait. Am J Surg. Dec 2006;192(6):756-61. [Medline].

  26. Strasberg SM, Clavien PA. Overview of therapeutic modalities for the treatment of gallstone diseases. Am J Surg. Apr 1993;165(4):420-6. [Medline].

  27. Swisher SG, Schmit PJ, Hunt KK, et al. Biliary disease during pregnancy. Am J Surg. Dec 1994;168(6):576-9; discussion 580-1. [Medline].

  28. Tait N, Little JM. The treatment of gall stones. BMJ. Jul 8 1995;311(6997):99-105. [Medline].

  29. Talley NJ. Gallstones and upper abdominal discomfort. Innocent bystander or a cause of dyspepsia?. J Clin Gastroenterol. Apr 1995;20(3):182-3. [Medline].

  30. Thomas SH, Borczuk P, Shackelford J. Patient and physician agreement on abdominal pain severity and need for opioid analgesia. Am J Emerg Med. Oct 1999;17(6):586-90. [Medline].

  31. Thomas SH, Silen W. Effect on diagnostic efficiency of analgesia for undifferentiated abdominal pain. Br J Surg. Jan 2003;90(1):5-9. [Medline].

  32. Thomas SH, Silen W, Cheema F. Effects of morphine analgesia on diagnostic accuracy in Emergency Department patients with abdominal pain: a prospective, randomized trial. J Am Coll Surg. Jan 2003;196(1):18-31. [Medline].

  33. Traverso LW. Clinical manifestations and impact of gallstone disease. Am J Surg. Apr 1993;165(4):405-9. [Medline].

  34. Tsimoyiannis EC, Antoniou NC, Tsaboulas C, Papanikolaou N. Cholelithiasis during pregnancy and lactation. Prospective study. Eur J Surg. Nov 1994;160(11):627-31. [Medline].

  35. Yusoff IF, Barkun JS, Barkun AN. Diagnosis and management of cholecystitis and cholangitis. Gastroenterol Clin North Am. Dec 2003;32(4):1145-68. [Medline].

  36. Zeman RK, Garra BS. Gallbladder imaging. The state of the art. Gastroenterol Clin North Am. Mar 1991;20(1):127-56. [Medline].

Further Reading

Contributor Information and Disclosures

Author

Rahul Sharma, MD, MBA, FACEP, Assistant Professor, Weill Medical College of Cornell University; Attending Physician, Department of Emergency Medicine, New York Presbyterian Hospital-Weill Cornell Medical Center
Rahul Sharma, MD, MBA, FACEP is a member of the following medical societies: American College of Emergency Physicians
Disclosure: Nothing to disclose.

Coauthor(s)

Peter A D Steel, MA, MBBS, Staff Physician, Department of Emergency Medicine, Joan and Sanford I Weill Medical College of Cornell and Columbia University College of Physicians and Surgeons, New York Presbyterian Hospitals
Peter A D Steel, MA, MBBS is a member of the following medical societies: American College of Emergency Physicians, British Medical Association, Emergency Medicine Residents Association, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Medical Editor

Samuel M Keim, MD, Associate Professor, Department of Emergency Medicine, University of Arizona College of Medicine
Samuel M Keim, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, American Public Health Association, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Eugene Hardin, MD, FAAEM, FACEP, Former Chair and Associate Professor, Department of Emergency Medicine, Charles Drew University of Medicine and Science; Former Chair, Department of Emergency Medicine, Martin Luther King Jr/Drew Medical Center
Disclosure: Nothing to disclose.

CME Editor

John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center
John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Chief Editor

Barry E Brenner, MD, PhD, FACEP, Professor of Emergency Medicine, Professor of Internal Medicine, Program Director, Emergency Medicine, University Hospitals, Case Medical Center
Barry E Brenner, MD, PhD, FACEP is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Chest Physicians, American College of Emergency Physicians, American College of Physicians, American Heart Association, American Thoracic Society, Arkansas Medical Society, New York Academy of Medicine, New York Academy of Sciences, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.